

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI623286

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	AstraZeneca UK Limited	07/24/2017
RECEIVING PARTY DATA		
Company Name:	Kudos Pharmaceuticals Limited	
Street Address:	1 Francis Crick Avenue	
Internal Address:	Cambridge Biomedical Campus	
City:	Cambridge	
State/Country:	UNITED KINGDOM	
Postal Code:	CB2 0AA	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Application Number:	18785063
	Application Number:	18785092
CORRESPONDENCE DATA		
Fax Number:	2024084000	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2024084000	
Email:	regional-desk@finnegan.com	
Correspondent Name:	Candace Walther	
Address Line 1:	901 New York Ave., NW	
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20001	
ATTORNEY DOCKET NUMBER:	09963.0102-05000	
NAME OF SUBMITTER:	Pam Gebhardtsbauer	
SIGNATURE:	Pam Gebhardtsbauer	
DATE SIGNED:	11/11/2024	
Total Attachments: 5		
source=CoverSheet-Assignment-AstraZenecaUKLimited-KudosPharmaceuticalsLimited#page1.tiff		
source=CoverSheet-Assignment-AstraZenecaUKLimited-KudosPharmaceuticalsLimited#page2.tiff		
source=CoverSheet-Assignment-AstraZenecaUKLimited-KudosPharmaceuticalsLimited#page3.tiff		
source=CoverSheet-Assignment-AstraZenecaUKLimited-KudosPharmaceuticalsLimited#page4.tiff		

RECORDATION FORM COVER SHEET
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies) AstraZeneca UK Limited Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party(ies) Name: <u>Kudos Pharmaceuticals Limited</u> Internal Address: _____ Street Address: <u>1 Francis Crick Avenue</u> <u>Cambridge Biomedical Campus</u> City: <u>Cambridge</u> State: _____ Country: <u>United Kingdom</u> Zip: <u>CB2 0AA</u> Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance/Execution Date(s): Execution Date(s) <u>July 24, 2017</u> <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Joint Research Agreement <input type="checkbox"/> Government Interest Assignment <input type="checkbox"/> Executive Order 9424, Confirmatory License <input type="checkbox"/> Other _____	4. Application or patent number(s): <input type="checkbox"/> This document serves as an Oath/Declaration (37 CFR 1.63). A. Patent Application No.(s) 18/785,063 18/785,092 Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No B. Patent No.(s)
5. Name and address to whom correspondence concerning document should be mailed: Name: <u>FINNEGAN, HENDERSON ET AL.</u> Internal Address: _____ Street Address: <u>901 New York Ave., NW</u> City: <u>Washington</u> State: <u>District of Columbia</u> Zip: <u>20001</u> Phone Number: <u>(202) 408-4000</u> Docket Number: <u>09963.0102-05000 and 09963.0102-06000</u> Email Address: <u>faxserve@finnegan.com</u>	6. Total number of applications and patents involved: <u>1</u> 7. Total fee (37 CFR 1.21(h) & 3.41) \$ _____ <input type="checkbox"/> Authorized to be charged to deposit account <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> None required (government interest not affecting title) 8. Payment Information Deposit Account Number _____ Authorized UserName _____
9. Signature: _____ / Candace Walther / _____ Signature Date Candace Walther / Reg. No. 79,185 Name of Person Signing Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450 <div style="text-align: right;">Total number of pages including cover sheet, attachments, and documents: 5</div>	

ASSIGNMENT OF PATENT RIGHTS

THIS ASSIGNMENT is made as of July 24, 2017 (the “**Effective Date**”) by and between

ASTRAZENECA UK LIMITED, a company organized and existing under the laws of England and Wales with registered number 03674842 with registered office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, UK CB2 0AA (“**Assignor**”); and

KUDOS PHARMACEUTICALS LIMITED, a company incorporated in England under no. 03479984, whose registered office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, England (“**Assignee**”).

WHEREAS, Assignor has agreed to assign to Assignee the Assignor’s entire right, title and interest in and to the patent applications identified in the attached Schedule (the “**Applications**”) and in and to the inventions and improvements disclosed in such Applications.

NOW THEREFORE IT IS HEREBY AGREED AS FOLLOWS:

1. In consideration of payments made by Assignee to Assignor, receipt of which is hereby acknowledged, the Assignor hereby assigns, with full title guarantee, free from all and any charges or other third party rights, to Assignee absolutely all their legal right, legal title and legal interest in and to the inventions, the Application and any patents or applications derived therefrom; any divisions, continuations and continuations-in-part thereof; any re-issues, re-examinations, or extensions thereof; all rights to claim priority on the basis of the Application and any patents or applications derived therefrom; and the right to file patent applications derived from the Application directly in the name of Assignee or an affiliated company of Assignee (in countries or regions where such filings are permissible) (collectively, the “**Rights**”), whether now existing or hereafter arising, to the full end of the term for which the Rights have been granted, reissued, re-examined or extended. Assignor acknowledges that Assignee shall have the rights to further assign or otherwise transfer any or all of the Rights to any third party and Assignor waives any right of first refusal that they may have for acquiring such Rights.
2. Assignor agrees with Assignee that their assignment to Assignee includes, but is not limited to, any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of the Rights, including all rights to recover damages, profits and injunctive relief for infringement of any of the Rights.
3. Assignor agrees with Assignee that they shall, at the expense of Assignee, execute and sign all such lawful instruments, applications and documents and do all such lawful acts and things as may reasonably be required by Assignee to enable Assignee or its successors, nominees or assigns to:
 - a) secure the vesting of the Rights in Assignee or in its successors, nominees or assigns;
 - b) defeat any challenge to the validity of and resolve any questions concerning the Rights; and
 - c) apply for, prosecute and obtain patent or similar protection in the United States and all other countries of the world for an invention embodied by the Rights, including the right to claim convention priority from such Patents and including, without limitation, cooperating in any proceedings involving examinations, re-examinations, reissues, opposition and cancellation proceedings, interferences, infringement proceedings, court actions and the like.
4. Assignor hereby authorizes the United States Commissioner of Patents and Trademarks and, as appropriate, the corresponding officials of other countries, to record this Assignment.


5. This assignment shall be governed by and construed in accordance with the laws of England and Wales and the parties hereby submit to the exclusive jurisdiction of the English courts.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

**Signed for and on behalf of
AstraZeneca UK Limited**



.....
Adrian Kemp
Company Secretary

Witnessed by:



.....
Witness name: SHARON POWER
Occupation: EXECUTIVE ASSISTANT
Address: 1 Francis Crick Avenue, Cambridge
Biomedical Campus, CB2 0AA

Date: 24 July 2017

**Signed for and on behalf of
KuDOS Pharmaceuticals Limited**


.....
Katie Jackson-Turner
Director

Witnessed by:


.....
Witness name: Liliane Teuken
Occupation: Personal Assistant
Address: 1 Francis Crick Avenue, Cambridge
Biomedical Campus, CB2 0AA

Date: 24 July 2017

THE SCHEDULE

APPLICATIONS			
Family Report - 103514 (Olaparib Tablet Formulation)			
Case reference	Filing Number	Publication Number	Grant Number
103514-AR-NP	090103865	AR073792A1	
103514-AT-EPT	09740728.2	2346495	E813480
103514-AU-PCT	2009300866		2009300866
103514-BB-PCT	2001/1610		
103514-BE-EPT	09740728.2	2346495	2346495
103514-BG-EPT	09740728.2	2346495	BG/EP 2346495 T3
103514-BR-PCT	PI0920604-3		
103514-CA-PCT	2737400		2737400
103514-CH-EPT	09740728.2	2346495	CY20161100928
103514-CL-PCT	0774-2011		53.226
103514-CN-PCT	200980150172.4	102238945	zl200980150172.4
103514-CR-PCT	2011-0186		
103514-CY-EPT	09740728.2	2346495	CY20161100928
103514-CZ-EPT	09740728.2	2346495	2346495
103514-DE-EPT	09740728.2	2346495	602009039839.3
103514-DK-EPT	09740728.2	2346495	2346495
103514-DO-PCT	P2011-0094		
103514-EA-EAT	201100595		020783
103514-EC-PCT	SP-11-10960		
103514-EE-EPT	09740728.2	2346495	2346495
103514-EG-PCT	492/2011		
103514-EP-EPT	09740728.2	2346495	2346495
103514-ES-EPT	09740728.2	2346495	2346495
103514-FI-EPT	09740728.2	2346495	2346495
103514-FR-EPT	09740728.2	2346495	2346495
103514-GB-EPT	09740728.2	2346495	2346495
103514-GG-FPR	2346495		
103514-GR-EPT	09740728.2	2346495	2346495
103514-GT-PCT	A-2011-000088		
103514-HK-FPR	11113088.3	1158528A	1158528B
103514-HN-PCT	2011-000947		5593
103514-HR-EPT	09740728.2	2346495	P20161154T
103514-HU-EPT	09740728.2	2346495	2346495
103514-ID-PCT	W-00201101570	0514031	ID P000041067
103514-IE-EPT	09740728.2	2346495	2346495
103514-IL-PCT	211809	12/2014	211809
103514-IN-PCT	514/MUMNP/2011		
103514-IS-EPT	09740728.2	2346495	2346495
103514-IT-EPT	09740728.2	2346495	502016000093807
103514-JP-PCT	2011-529638	2012-505158	5524220
103514-KR-PCT	10-2011-7008906		1668499
103514-KZ-EAT	201100595		020783

APPLICATIONS			
Family Report - 103514 (Olaparib Tablet Formulation)			
Case reference	Filing Number	Publication Number	Grant Number
103514-LT-EPT	09740728.2	2346495	2346495
103514-LU-EPT	09740728.2	2346495	2346495
103514-LV-EPT	09740728.2	2346495	2346495
103514-ME-EPT	09740728.2	2346495	P-2016/204
103514-MK-EPT	09740728.2	2346495	MK/P-2016/633
103514-MO-FPR	J/001603		J/001603
103514-MT-EPT	09740728.2	2346495	2346495
103514-MX-PCT	11/3740		
103514-MY-PCT	PI2011001567		
103514-NI-PCT	2011-000070		
103514-NL-EPT	09740728.2	2346495	2346495
103514-NO-EPT	09740728.2	2346495	2346495
103514-NZ-PCT	592719		592719
103514-PE-PCT	000857.2011		7306
103514-PH-PCT	1-2011-500682		1-2011-500682
103514-PK-NP	905/2009		
103514-PL-EPT	09740728.2	2346495	2346495
103514-PT-EPT	09740728.2	2346495	2346495
103514-RO-EPT	09740728.2	2346495	1024661
103514-RS-EPT	09740728.2	2346495	P-2016/0768
103514-RU-EAT	201100595		020783
103514-SA-NP	109300599		3302
103514-SE-EPT	09740728.2	2346495	2346495
103514-SG-PCT	201102044-3		169789
103514-SI-EPT	09740728.2	2346495	2346495
103514-SK-EPT	09740728.2	2346495	2346495
103514-SM-EPT	09740728.2	2346495	2346495
103514-SV-PCT	E-3875-2011		
103514-TH-NP	0901004528		
103514-TR-EPT	09740728.2	2346495	2016/12951
103514-TT-PCT	TT/A/2011/00052		
103514-TW-NP	98133889		1461418
103514-UA-PCT	A201105678		106878
103514-US-CNT[3]	15/449,353	US-2017-0173010-A1	
103514-US-NP	12/574801	2010-0098763A1	8475842
103514-US-PSP	61/103347		
103514-UY-NP	32162		
103514-VE-NP	1829/09		
103514-VN-PCT	1-2011-00851	27949	
103514-ZA-PCT	2011/03333		2011/03333